Unbound MEDLINE

Retrospective comparison of caffeine and doxapram for the treatment of hypercapnia in foals with hypoxic-ischemic encephalopathy. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine [J Vet Intern Med] Journal article

 
Giguère S, Slade JK, Sanchez LC 
Retrospective comparison of caffeine and doxapram for the treatment of hypercapnia in foals with hypoxic-ischemic encephalopathy. [Journal Article]
J Vet Intern Med 2008 Mar-Apr; 22(2):401-5.


Background: Despite a lack of data regarding their efficacy, both caffeine and doxapram have been recommended for treatment of hypercapnia in equine neonates with central nervous system damage. Hypothesis: Caffeine and doxapram alleviate hypercapnia in foals with hypoxic-ischemic encephalopathy. Animals: Sixteen foals treated with either caffeine (n = 8) or doxapram (n = 8).
Methods: Information on age, body temperature, heart rate, respiratory rate, arterial blood gas parameters, duration of therapy, and outcome was abstracted from each medical record.
Results: Therapy with doxapram resulted in a significant decrease in partial pressure of carbon dioxide (PaCO(2) [P= .004]), bicarbonate concentration (P= .002), and base excess (P= .005) compared with baseline values but failed to correct acidemia. In contrast, administration of caffeine did not result in significant changes from baseline values. The percentage decrease in PaCO(2) and bicarbonate concentration was significantly greater in foals treated with doxapram than in foals treated with caffeine (P= .004). The proportions of foals that achieved the targeted PaCO(2) (</= 50 mmHg) were significantly higher in foals treated with doxapram than in foals treated with caffeine (P= .029). The proportion of survivors in the 2 treatment groups was not significantly different. Conclusions and Clinical Importance: Doxapram is more effective than caffeine for rapid correction of hypercapnia in foals with hypoxic-ischemic encephalopathy.



More from this journal
  
Advertise on this site.